Drug intelligence / Profile preview

statin + aspirin

Development stage
Unknown
Lead developer
Merck
Modality
Small Molecules
Administration
Oral
01

Overview

Statin + aspirin refers to a fixed-dose combination of a statin (such as atorvastatin or rosuvastatin) and the antiplatelet agent aspirin. Statins are HMG-CoA reductase inhibitors that lower cholesterol by inhibiting the enzyme responsible for cholesterol synthesis in the liver. Aspirin is an antiplatelet agent that irreversibly inhibits cyclooxygenase-1 (COX-1), reducing thromboxane A2 production and thereby inhibiting platelet aggregation. The combination is primarily used for secondary prevention of cardiovascular events such as heart attack and stroke in patients at high risk due to established cardiovascular disease or multiple risk factors. This dual therapy targets both lipid lowering (statins) and reduction of thrombotic events (aspirin), providing additive benefits in reducing major adverse cardiovascular outcomes[2][4][5][6].

Brand names
Ecosprin AVAztor AspAtorva AspModlip ASGMactor ASPAtorlip-ASPAtorec-ASPLipikind-ASLipicure-ASTonact-ASP
Other names
atorvastatin + aspirinrosuvastatin + aspirinpravastatin + aspirin
02

Targets

HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on statin + aspirin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on statin + aspirin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call